{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:06:53Z","timestamp":1753877213901,"version":"3.41.2"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The primary objective of this study was to assess the impact of extramusculoskeletal manifestations (EMMs) and peripheral musculoskeletal features on first biologic drug survival in subjects with axial spondyloarthritis (axSpA). The secondary objective was to evaluate the impact of reasons for treatment discontinuation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A total of 593 axSpA patients from the SpondyloArthritis Research Consortium of Canada initiating a first biologic drug were identified between 2003 and 2023. Drug survival was presented using Kaplan\u2013Meier curves for each disease manifestation and compared using the logrank test. A Cox proportional hazards model was used to analyse independent predictors of discontinuation. The impact of reasons for treatment discontinuation was assessed using a competing risk analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The presence of psoriasis, nail psoriasis, dactylitis, at least one EMM or at least one peripheral musculoskeletal manifestation was associated with prolonged drug survival compared with subjects without these disease manifestations. In multivariable analysis, psoriasis [hazard ratio (HR) 0.53 (95% CI 0.33, 0.86)] and at least one peripheral musculoskeletal manifestation [HR 0.65 (95% CI 0.47, 0.92)] were independently associated with a lower risk for biologic discontinuation. The presence of psoriasis or dactylitis was associated with reduced treatment discontinuation in patients who stopped their biologic medication for ineffectiveness but not when treatment was discontinued due to adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study showed that the presence of some axSpA disease manifestations were associated with prolonged biologic drug survival. Psoriasis and peripheral musculoskeletal manifestations were the most significant predictors of treatment retention. Future research will be needed to further refine treatment strategies according to specific disease manifestations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rap\/rkaf004","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T14:20:58Z","timestamp":1738246858000},"source":"Crossref","is-referenced-by-count":0,"title":["Impact of disease manifestations on first biologic drug survival in axial spondyloarthritis: a real-life Canadian study"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4155-2963","authenticated-orcid":false,"given":"Rapha\u00ebl","family":"Hurtubise","sequence":"first","affiliation":[{"name":"Department of Medicine, Universit\u00e9 de Montr\u00e9al , Montreal, QC,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8949-4198","authenticated-orcid":false,"given":"Sherry","family":"Rohekar","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Western University , London, ON,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3210-4771","authenticated-orcid":false,"given":"Nigil","family":"Haroon","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, University Health Network , Toronto, ON,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeynep","family":"Baskurt","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, University Health Network , Toronto, ON,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Chim","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, University Health Network , Toronto, ON,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9296-2842","authenticated-orcid":false,"given":"Michel","family":"Zummer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universit\u00e9 de Montr\u00e9al , Montreal, QC,","place":["Canada"]},{"name":"Division of Rheumatology, H\u00f4pital Maisonneuve Rosemont , Montreal, QC,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4750-1422","authenticated-orcid":false,"given":"Robert D","family":"Inman","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, University Health Network , Toronto, ON,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3683-8713","authenticated-orcid":false,"given":"Nicolas","family":"Richard","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universit\u00e9 de Montr\u00e9al , Montreal, QC,","place":["Canada"]},{"name":"Division of Rheumatology, H\u00f4pital Maisonneuve Rosemont , Montreal, QC,","place":["Canada"]},{"name":"Centre de Recherche de l\u2019H\u00f4pital Maisonneuve-Rosemont , Montreal, QC,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"SpondyloArthritis Research Consortium of Canada (SPARCC)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert D","family":"Inman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dafna","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigil","family":"Haroon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherry","family":"Rohekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tristan","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Proton","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Richard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Zummer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carter","family":"Thorne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bindu","family":"Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirley","family":"Tse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dianne","family":"Mosher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Ziouzina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Tsoukas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dax","family":"Rumsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibel","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihi","family":"Eder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Starr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Fortin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Bessette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"2025030418595065400_rkaf004-B1","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1136\/ard.2009.108217","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2025030418595065400_rkaf004-B2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025030418595065400_rkaf004-B3","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.1097\/RHU.0000000000001693","article-title":"First biologic drug persistence in patients with ankylosing spondylitis and nonradiographic axial spondyloarthritis: a real-world Canadian physicians\u2019 experience","volume":"28","author":"Ngo","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"2025030418595065400_rkaf004-B4","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3899\/jrheum.081048","article-title":"Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis","volume":"36","author":"Rudwaleit","year":"2009","journal-title":"J Rheumatol"},{"key":"2025030418595065400_rkaf004-B5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3899\/jrheum.160958","article-title":"Ankylosing spondylitis versus nonradiographic axial spondyloarthritis: comparison of tumor necrosis factor inhibitor effectiveness and effect of HLA-B27 status. An observational cohort study from the Nationwide DANBIO Registry","volume":"44","author":"Glintborg","year":"2017","journal-title":"J Rheumatol"},{"key":"2025030418595065400_rkaf004-B6","doi-asserted-by":"crossref","first-page":"e000017","DOI":"10.1136\/rmdopen-2014-000017","article-title":"Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis","volume":"1","author":"Maneiro","year":"2015","journal-title":"RMD Open"},{"key":"2025030418595065400_rkaf004-B7","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s13075-021-02647-z","article-title":"A cluster analysis of patients with axial spondyloarthritis using tumour necrosis factor alpha inhibitors based on clinical characteristics","volume":"23","author":"Lee","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2025030418595065400_rkaf004-B8","first-page":"1701","article-title":"Biologic retention rate and efficacy in patients with cluster-based phenotypes of ankylosing spondylitis: data from a Korean national biologics registry","volume":"40","author":"Min","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2025030418595065400_rkaf004-B9","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4081\/reumatismo.2014.756","article-title":"Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNF\u03b1 drugs","volume":"66","author":"Perrotta","year":"2014","journal-title":"Reumatismo"},{"key":"2025030418595065400_rkaf004-B10","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/rheumatology\/ket249","article-title":"Remission in ankylosing spondylitis treated with anti-TNF-\u03b1 drugs: a national multicentre study","volume":"52","author":"Spadaro","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"2025030418595065400_rkaf004-B11","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/rheumatology\/kez657","article-title":"Predicting response to anti-TNF\u03b1 therapy among patients with axial spondyloarthritis (axSpA): results from BSRBR-AS","volume":"59","author":"Macfarlane","year":"2020","journal-title":"Rheumatology"},{"key":"2025030418595065400_rkaf004-B12","first-page":"1751","article-title":"Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept","volume":"32","author":"Davis","year":"2005","journal-title":"J Rheumatol"},{"key":"2025030418595065400_rkaf004-B13","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1093\/rheumatology\/keq129","article-title":"Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis","volume":"49","author":"Braun","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2025030418595065400_rkaf004-B14","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.3390\/jcm13071855","article-title":"Different therapeutic response to anti-TNF drugs in patients with axial spondyloarthritis depending on their clinical profile: an unsupervised cluster analysis","volume":"13","author":"Priego-P\u00e9rez","year":"2024","journal-title":"J Clin Med"},{"key":"2025030418595065400_rkaf004-B15","doi-asserted-by":"crossref","first-page":"e000762","DOI":"10.1136\/rmdopen-2018-000762","article-title":"Impact of extra-articular spondyloarthritis manifestations and comorbidities on drug retention of a first TNF-inhibitor in ankylosing spondylitis: a population-based nationwide study","volume":"4","author":"Lindstr\u00f6m","year":"2018","journal-title":"RMD Open"},{"key":"2025030418595065400_rkaf004-B16","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1007\/s10067-018-4290-0","article-title":"The effect of extra-articular manifestations on tumor necrosis factor-\u03b1 inhibitor treatment duration in patients with ankylosing spondylitis: nationwide data from the Korean College of Rheumatology BIOlogics (KOBIO) registry","volume":"37","author":"Kim","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2025030418595065400_rkaf004-B17","doi-asserted-by":"crossref","first-page":"e002802","DOI":"10.1136\/rmdopen-2022-002802","article-title":"Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA)","volume":"9","author":"Dougados","year":"2023","journal-title":"RMD Open"},{"key":"2025030418595065400_rkaf004-B18","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00296-022-05213-1","article-title":"Drug retention rate and predictive factors of drug survival for secukinumab in radiographic axial spondyloarthritis","volume":"43","author":"Arma\u011fan","year":"2023","journal-title":"Rheumatol Int"},{"key":"2025030418595065400_rkaf004-B19","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2025030418595065400_rkaf004-B20","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1136\/ard.2008.100826","article-title":"ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis","volume":"68","author":"van der Heijde","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2025030418595065400_rkaf004-B21","first-page":"2281","article-title":"A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index","volume":"21","author":"Calin","year":"1994","journal-title":"J Rheumatol"},{"key":"2025030418595065400_rkaf004-B22","first-page":"1694","article-title":"Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index","volume":"21","author":"Jenkinson","year":"1994","journal-title":"J Rheumatol"},{"key":"2025030418595065400_rkaf004-B23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.62.1.20","article-title":"Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis","volume":"62","author":"Doward","year":"2003","journal-title":"Ann Rheum Dis"},{"volume-title":"SF-36 physical and mental health summary scales: a user\u2019s manual","year":"1994","author":"Ware","key":"2025030418595065400_rkaf004-B24"},{"year":"2024","author":"Therneau","key":"2025030418595065400_rkaf004-B25"},{"key":"2025030418595065400_rkaf004-B26","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4419-6646-9","volume-title":"Survival analysis: a self-learning text","author":"Kleinbaum","year":"2012","edition":"3rd ed."},{"key":"2025030418595065400_rkaf004-B27","first-page":"65","article-title":"A simple sequentially rejective multiple test procedure","volume":"6","author":"Holm","year":"1979","journal-title":"Scand J Stat"},{"volume-title":"R: a language and environment for statistical computing","year":"2023","author":"R Core Team","key":"2025030418595065400_rkaf004-B28"},{"key":"2025030418595065400_rkaf004-B29","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3899\/jrheum.190299","article-title":"Comparative persistence of methotrexate and tumor necrosis factor inhibitors in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","volume":"47","author":"George","year":"2020","journal-title":"J Rheumatol"},{"key":"2025030418595065400_rkaf004-B30","doi-asserted-by":"crossref","first-page":"708168","DOI":"10.3389\/fmed.2021.708168","article-title":"Real-life retention rates and reasons for switching of biological DMARDs in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","volume":"8","author":"Bhushan","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2025030418595065400_rkaf004-B31","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/annrheumdis-2013-203582","article-title":"Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis","volume":"74","author":"Stolwijk","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025030418595065400_rkaf004-B32","doi-asserted-by":"crossref","first-page":"e002956","DOI":"10.1136\/rmdopen-2022-002956","article-title":"Characterisation of patients with axial psoriatic arthritis and patients with axial spondyloarthritis and concomitant psoriasis in the SCQM registry","volume":"9","author":"Ciurea","year":"2023","journal-title":"RMD Open"},{"key":"2025030418595065400_rkaf004-B33","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/rheumatology\/kez457","article-title":"Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis?","volume":"59","author":"Feld","year":"2020","journal-title":"Rheumatology"},{"key":"2025030418595065400_rkaf004-B34","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s13555-022-00760-8","article-title":"Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: a systematic literature review and a network meta-analysis","volume":"12","author":"Armstrong","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025030418595065400_rkaf004-B35","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/acr.20258","article-title":"Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register","volume":"62","author":"Kristensen","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025030418595065400_rkaf004-B36","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1093\/rheumatology\/kead665","article-title":"Regional differences in clinical phenotype of axial spondyloarthritis: results from the International Map of Axial Spondyloarthritis (IMAS)","volume":"63","author":"Poddubnyy","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2025030418595065400_rkaf004-B37","doi-asserted-by":"crossref","first-page":"e222312","DOI":"10.1001\/jamanetworkopen.2022.2312","article-title":"Predicting probability of response to tumor necrosis factor inhibitors for individual patients with ankylosing spondylitis","volume":"5","author":"Wang","year":"2022","journal-title":"JAMA Netw Open"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/9\/1\/rkaf004\/61381632\/rkaf004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/9\/1\/rkaf004\/61381632\/rkaf004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T20:59:20Z","timestamp":1741121960000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkaf004\/7945675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,18]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkaf004","relation":{},"ISSN":["2514-1775"],"issn-type":[{"type":"electronic","value":"2514-1775"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2024,12,18]]},"article-number":"rkaf004"}}